CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 127 enrolled
Drug / intervention
alcaftadine 0.25% ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01470118
NCT01470118Phase 4Completed
CompareCT.gov

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Allergan·interventional·Posted Nov 11, 2011·Updated Feb 21, 2013

In Brief

A Phase 4 clinical trial evaluating alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 127 participants across 1 site.

Detailed Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.6 years ago

Interventions

alcaftadine 0.25% ophthalmic solutiondrug

One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.

olopatadine 0.2% ophthalmic solutiondrug

One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.

dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%drug

One drop of placebo instilled in each eye at Day 0 and Day 14.